Literature DB >> 20111854

[Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy].

J Bauer1, C Pfeiffer, W Burr.   

Abstract

We evaluated factors possibly influencing serum concentrations of levetiracetam (LEV-SC). The study included 163 patients with epilepsy (91 men, 72 women; mean age 39.6 years). The duration of treatment on first analysis was 226 days; the mean daily dose amounted to 2,434 mg. In each patient between one and seven measurements were carried out (mean 2.2). LEV-SC significantly depended on daily dosage and the interval between the time the medication was taken and the time of blood extraction. A marked drop in LEV-SC was observed 4-5 h following ingestion. Carbamazepine, oxcarbazepine and clobazam reduced LEV-SC, whereas valproate elevated LEV-SC significantly. When assessing evaluation of compliance these factors have to be taken into consideration when comparing intraindividual LEV-SC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20111854     DOI: 10.1007/s00115-009-2906-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  13 in total

Review 1.  Pharmacokinetics of levetiracetam.

Authors:  R A Radtke
Journal:  Epilepsia       Date:  2001       Impact factor: 5.864

Review 2.  Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

Authors:  M Schulz; A Schmoldt
Journal:  Pharmazie       Date:  2003-07       Impact factor: 1.267

Review 3.  [Therapeutic drug monitoring in epileptology and psychiatry].

Authors:  C Brandt; P Baumann; G Eckermann; C Hiemke; T W May; B Rambeck; B Pohlmann-Eden
Journal:  Nervenarzt       Date:  2008-02       Impact factor: 1.214

4.  Levetiracetam: a long-term follow-up study of efficacy and safety.

Authors:  J Bauer; E Ben-Menachem; G Krämer; W Fryze; S Da Silva; D G A Kasteleijn-Nolst Trenité
Journal:  Acta Neurol Scand       Date:  2006-09       Impact factor: 3.209

Review 5.  Is there a role for therapeutic drug monitoring of new anticonvulsants?

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 6.  The new generation of antiepileptic drugs: advantages and disadvantages.

Authors:  E Perucca
Journal:  Br J Clin Pharmacol       Date:  1996-11       Impact factor: 4.335

7.  Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy.

Authors:  Bernhard Rambeck; Uwe H Jürgens; Theodor W May; Heinz Wolfgang Pannek; Friedrich Behne; Alois Ebner; Ali Gorji; Heidrun Straub; Erwin-Josef Speckmann; Bernd Pohlmann-Eden; Wolfgang Löscher
Journal:  Epilepsia       Date:  2006-04       Impact factor: 5.864

8.  Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.

Authors:  Isabelle Ragueneau-Majlessi; Rene H Levy; Franz Janik
Journal:  Epilepsia       Date:  2002-07       Impact factor: 5.864

9.  Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.

Authors:  René Coupez; Jean-Marie Nicolas; Thomas R Browne
Journal:  Epilepsia       Date:  2003-02       Impact factor: 5.864

10.  Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication.

Authors:  Theodor W May; Bernhard Rambeck; Uwe Jürgens
Journal:  Ther Drug Monit       Date:  2003-12       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.